오름테라퓨틱

475830KOSDAQ

42.9 / 100

Reference Date: 2026-09-08

Financial Score12.0 / 40

News Sentiment15.9 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 12.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Orm Therapeutics is a clinical-stage biotech company developing antibody-based targeted protein degradation (TPD²®) therapies to treat cancer. Its key candidates, ORM-5029 and ORM-1153, target HER2-positive breast cancer and hematologic malignancies, with ORM-5029 in Phase 1 trials and ORM-1153 preparing for IND submission in 2026. TPD² combines ADC technology to deliver protein degraders selectively to cancer cells, minimizing off-target effects and enhancing therapeutic efficacy.

Number of Employees

21people

Average Salary

174.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

8.98Industry Average 1.200.0Point

7.5x industry avg (risky)

ROE

-33.22Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

17.44Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼99.9% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼521.0% (1-year basis)

ROE Trend

0.0 / 4

Detailed News Sentiment

10 totalPositive 4Neutral 4Negative 2Average Sentiment Score 63.5

Neutral
DGIST 혁신창업원 '2026 창업주간' 개최… 명사 7인 릴레이 특...
DGIST의 혁신창업원 출범 기념 행사는 관련 스타트업에 대한 관심을 높일 수 있으나, 오름테라퓨틱의 직접적인 영향은 제한적입니다.
Positive
'최저 경쟁률' 스카이랩스, 코스닥 입성?네오사피엔스 수요예측 [IPO...
스카이랩스의 낮은 경쟁률과 긍정적인 수요예측으로 인해 코스닥 상장이 예상되며, 이는 오름테라퓨틱에 긍정적인 영향을 미칠 것으로 보인다.
Neutral
[대형VC 대해부]⑨초기 발굴기업이 그룹사 인프라로…KB인베의 딥테크....
KB인베의 대규모 벤처투자 전략 발표로 시장 규모 확대는 확인되나, 오름테라퓨틱에 직접적인 영향은 제한적.

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 54,100Won52-week high 143,70052-week low 30,900

1-month return1.0Point

1m -12.60% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral기업설명회(IR)개최2026-08-31
Neutral전환주식의전환가액조정 (전환우선주)2026-08-18
Neutral전환주식의전환가액조정 (전환우선주)2026-08-14
Neutral반기보고서 (2026.06)2026-08-14